Novel drug delivery systems

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Anticancer drug development is rapidly evolving with novel therapeutic strategies.
• Several new therapies, including cytokine inducers, cell cycle modulators, monoclonal antibodies, anti-angiogenic compounds, gene therapy, antisense therapy, and vaccines, are emerging.
• These advancements necessitate updated research and clinical trial guidelines.

Purpose of the Study:

• To review novel approaches in anticancer drug development.
• To highlight the need for new guidelines in preclinical and clinical research for these therapies.
• To emphasize the challenge of identifying surrogate endpoints for efficacy.

Main Methods:

• Literature review of recent advancements in anticancer drug development.
• Analysis of emerging therapeutic modalities and their clinical translation.
• Discussion of the implications for preclinical and clinical trial design.

Main Results:

• A diverse range of novel anticancer therapies have been developed and some are entering clinical use.
• These include immunotherapies, targeted therapies, and genetic/nucleic acid-based treatments.
• The complexity of these new agents poses challenges for traditional research and trial methodologies.

Conclusions:

• The landscape of cancer treatment is being transformed by innovative drug development.
• Establishing clear guidelines for preclinical research and early-phase clinical trials (Phase I and II) is essential.
• The identification and validation of surrogate endpoints are critical for efficient evaluation of novel anticancer agents.